Abstract
Purpose
Hepatocellular carcinoma (HCC) is a life-threatening condition with only one drug treatment regimen approved for use. Oncolytic nucleosides are minimally effective against HCC putatively because of their inability to achieve cytotoxic levels of the active metabolite [nucleoside triphosphate (NTP)] in tumor cells at doses that are well tolerated. The aim of our studies was to explore the utility of CYP3A-activated prodrugs of cytarabine and fludarabine monophosphate for the treatment of HCC.
Methods
Prodrugs of cytarabine and fludarabine monophosphates were evaluated for their ability to safely achieve NTP levels in the liver of normal mice that are cytotoxic to hepatoma cells.
Results
While therapeutic levels of NTPs are achieved in the livers of normal rodents after administration of the prodrugs, only MB07133 achieved these levels whithout exhibiting signs of liver toxicity or myelosuppression.
Conclusions
As the levels of araCTP achieved in the liver at therapeutic doses are only toxic to proliferating cells (such as those in HCC tumors), but not the non-proliferative adjacent tissue, MB07133 treatment has the potential to be both efficacious and well tolerated in HCC patients.
Similar content being viewed by others
References
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300
Avramis VI, Plunkett W (1982) Metabolism and therapeutic efficacy of 9-beta-d-arabinofuranosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 42:2587–2591
Befeler AS, Di Bisceglie AM (2002) Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122:1609–1619
Befeler AS, Hayashi PH, Di Bisceglie AM (2005) Liver transplantation for hepatocellular carcinoma. Gastroenterology 128:1752–1764
Biro V, Goldenberg DM (1971) Hematological toxicity of 1-beta-d-arabinofyranosylcytosine, and its prevention by deoxycytidine, in the mouse. Chemotherapy 16:29–43
Boyer SH, Sun Z, Jiang H, Esterbrook J, Gomez-Galeno JE, Craigo W, Reddy KR, Ugarkar BG, MacKenna DA, Erion MD (2006) Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-d-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem 49:7711–7720
Braess J, Voss S, Jahns-Streubel G, Schoch C, Haferlach T, Kern W, Keye S, Schleyer E, Hiddemann W (2000) The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity. Br J Haematol 110:170–179
Camiener GW, Smith CG (1965) Studies of the enzymatic distribution of cytosie arabinoside-I. Enzyme distribution and species specificity. Biochem Pharmacol 14:1405–1416
Chaube S, Kreis W, Uchida K, Murphy ML (1968) The teratogenic effect of 1-β-d-arabinofuranosylcytosine in the rat: protection by deoxycytidine. Biochem Pharmacol 17:1213–1216
Danhauser L, Plunkett W, Keating M, Cabanillas F (1986) 9-beta-d-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18:145–152
Durham JP, Ives DH (1969) Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-d-arabinofuranosylcytosine phosphorylation. Mol Pharmacol 5:358–375
El Mouelhi M, Didolkar MS, Elias EG, Guengerich FP, Kauffman FC (1987) Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res 47:460–466
Erion MD, Reddy KR, Boyer SH, Matelich MC, Gomez-Galeno J, Lemus RH, Ugarkar BG, Colby TJ, Schanzer J, Van Poelje PD (2004) Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc 126:5154–5163
Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, Bullough DA (2005) Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 312:554–560
Gandhi V, Plunkett W (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93–103
Gandhi V, Estey E, Du M, Keating MJ, Plunkett W (1997) Minimum dose of fludarabine for the maximal modulation of 1-beta-d-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 3:1539–1545
Garrett C, Santi D (1979) A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem 99:268–273
Grasl-Kraupp B, Rutttkay-Nedecky B, Mullauer L, Taper H, Huber W, Brusch W, Schulte-Herman R (1997) Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 25:906–912
Graziadei I, Kelly T, Schirmer M, Geisen FH, Vogel W, Konwalinka G (1998) Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′, 2′-difluorodeoxycytidine on human hepatoma HepG2 cells. J Hepatol 28:504–509
Harrison SD Jr, Burdeshaw JA, Crosby RG, Cusic AM, Denine EP (1978) Hematology and clinical chemistry reference values for C57BL/6 X DBA/2 F1 mice. Cancer Res 38:2636–2639
Harvey WH, Fleming TR, Beltran G, Saiers JH, Oishi N, Von Hoff DD (1987) Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group study. Cancer Treat Rep 71:1111–1112
Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC, Bussolati B, Camussi G (2006) Isolation and characterization of a stem cell population from adult human liver. Stem Cells 24:2840–2850
Imagawa D, Ma B, Venook AP, Bissell M, Peterson C, Erion MD, NIculae I, Jensen J, Bullough D, Foyt HL (2007) A Phase I/II study to assess the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) infusion of MB07133 in subjects with unresectable hepatocellular carcinoma (HCC). In: AACR. American Association for Cancer Research Annual Meeting Proceedings, Los Angeles, CA. Abstract# 2649
Jamieson GP, Snook MB, Wiley JS (1990) Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk Res 14:475–479
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul J-L, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J (2007) Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). ASCO. J Clin Oncol Abstract# 4587
Montag A, Steward K, Rolzin P, Linemeyer DL, Erion MD (2004) The effect of dexamethasone treatment on CYP3A and activity distribution, the liver targeting of MB07133 and CYP3A activity in a highly proliferating state in rats. Hepatology 40: Abstract #649A
Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N (2006) Hepatocellular carcinoma. An overview. Ann Hepatol 5:16–24
Murray GI, Paterson PJ, Weaver RJ, Ewen SWB, Melvin WT, Burke MD (1993) The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma. Cancer 71:36–43
Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364–373
Ogiso T, Tatematsu M, Tamano S, Hasegawa R, Ito N (1990) Correlation between medium-term liver bioassay system data and results of long-term testing in rats. Carcinogenesis 11:561–566
Padgham CR, Boyle CC, Wang XJ, Raleigh SM, Wright MC, Paine AJ (1993) Alteration of transcription factor mRNAs during the isolation and culture of rat hepatocytes suggests the activation of a proliferative mode underlies their de-differentiation. Biochem Biophys Res Commun 197:599–605
Pallavicini MG (1984) Cytosine arabinoside: molecular, pharmacokinetic and cytokinetic considerations. Pharmacol Ther 25:207–238
Plunkett W, Hug V, Keating MJ, Chubb S (1980) Quantitation of 1-ß-d-arabinofuranosylcytosine 5’-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-ß-d-arabinofuranosylcytosine therapy. Cancer Res 40:588–591
Rodriguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, Gomez-Lechon MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32:505–520
Roskams T (2006) Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 25:3818–3822
Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (1992) Metabolism and disposition of gemcitabine, an oncolytic deoxycitidine analog, in mice, rats and dogs. Drug Metab Dispos 20:849–855
Suto T, Miyazawa J, Watanabe Y, Suto K, Yoshida Y, Sakata Y (1997) The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma. Semin Oncol 24(S6):122–129
Thorgeirsson SS, Factor VM, Snyderwine EG (2000) Transgenic mouse models in carcinogenesis research and testing. Toxicol Lett 112–113:553–555
Tobias SC, Borch RF (2004) Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm 1:112–116
Venook AP (2004) Key research issues in the management of hepatocellular carcinoma. Cancer Chemother Pharmacol 54(Suppl 1):S87–S90
Weber E, Bannasch P (1994) Dose and time dependence of the cellular phenotype in rat hepatic preneoplasia and neoplasia induced by continuous oral exposure to N-nitrosomorpholine. Carcinogenesis 15:1235–1242
Zhang YJ, Chen S, Tsai WY, Ahsan H, Lunn RM, Wang LY, Chen CJ, Santella RM (2000) Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1 and 4-aminobiphenyl DNA adducts. Biomarkers 5:295–306
Acknowledgments
The authors would like to thank Paul Rolzin and Barbara Treash-Osio for their technical assistance in the conduct of the studies described herein. We would also like to thank Dr. Paul D. van Poelje for editorial assistance and scientific input throughout the conduct of these studies. We would like to acknowledge the efforts of Dr. Sanna Rosengren whose initial work on this project lead to the discoveries described herein.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
MacKenna, D.A., Montag, A., Boyer, S.H. et al. Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma. Cancer Chemother Pharmacol 64, 981–991 (2009). https://doi.org/10.1007/s00280-009-0953-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-0953-5